Compass Therapeutics (CMPX) Projected to Post Earnings on Thursday

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Compass Therapeutics to post earnings of ($0.10) per share for the quarter.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). On average, analysts expect Compass Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Compass Therapeutics Trading Down 0.8 %

CMPX stock opened at $2.51 on Thursday. The company has a market cap of $347.09 million, a P/E ratio of -6.78 and a beta of 1.19. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $4.08. The company's 50-day moving average price is $2.77 and its 200 day moving average price is $2.03.

Analyst Upgrades and Downgrades

CMPX has been the topic of several recent research reports. Piper Sandler initiated coverage on shares of Compass Therapeutics in a report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price target on the stock. Leerink Partnrs lowered shares of Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, November 15th. Guggenheim initiated coverage on shares of Compass Therapeutics in a research report on Monday, February 24th. They set a "buy" rating and a $12.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $32.00 price target on shares of Compass Therapeutics in a research report on Tuesday, February 25th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $11.38.

Remove Ads

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.